Kaleido Biosciences welcomes Jean Mixer to its Board of Directors

– USA, MA –  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Jean Mixer has been appointed to its Board of Directors.

“I want to thank Jon for his service as a Kaleido Director during an important time in the Company’s evolution, and welcome Jean to the Board. We are thrilled to have her tremendous experience and strategic insights across a broad range of areas in healthcare, from implementing digital strategies to assisting organizations as they build and transform their businesses. We look forward to benefiting from her insights as we continue our mission to lead a revolution in human health,” said Michael Bonney, Executive Chair of Kaleido.

Ms. Mixer will assume the seat of Jonathan McIntyre, Ph.D., who is stepping off the Board to focus on his role as CEO of Motif FoodWorks.

About Jean Mixer

Ms. Mixer has more than 25 years of experience in healthcare and is currently Chief Digital Transformation Officer and Vice President, Strategy at Boston Children’s Hospital. Previously, she launched and ran her own consulting firm, and served for more than a decade as a partner at the Boston Consulting Group. Ms. Mixer has experience across the healthcare industry, including working with executive management and Boards of leading academic medical centers, integrated healthcare delivery networks, payers, pharmacy/PBMs and biopharmaceutical and medical device companies. She began her career as an officer at J.P. Morgan in New York. She previously served on the Board of Directors of two public companies, Cambridge Trust and NxStage Medical, which was acquired by Fresenius Medical Care for $2 billion in February 2019.

“I am excited to be joining the Board of a company committed to breaking the mold of traditional discovery and development as well as leading an innovative approach to targeting the potential of the microbiome to improve health and treat disease,” said Ms. Mixer.

She received a master’s degree in Management from the Kellogg School of Management.

About Kaleido Biosciences

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies. MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

For more information: https://kaleido.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>